Antibody generation

Display technologies have evolved from the outset and have now proved to be very useful when it comes to the task of selecting specific antibodies. Most of the selected antibodies via these platforms still need to be modified for their use in humans. At the same time they are restricted in their antigen recognition. These platforms are not well suited for in vivo selections. A novel cell-based antibody display platform is designed to help now. The validation of antibodies on the surface of T lymphocytes that can be used as part of a chimeric-immune receptor (CIR) mediating signaling ideal index the antigen-antibody interaction to show a demonstrable change in the T-cell phenotype. With this method an in vitro selection with a lentiviral-transduced human T-cell line worked successfully. A tumor-specific CIR on the surface of the cell was verified as an expression of carcino embryonic antigen. Based on effective interaction between the CIR and the tumor antigen, it was shown that the combination of CIR-mediated activation by FACS sorting of CD69 + T cells, it is possible to isolate the tumor by indication for a specific cell surface antigen. There was an accumulation of at least 103-fold after two passes, which led to a homogeneous population of T cells, which led to tumor-specific CIRS.

This entry was posted on Friday, October 2nd, 2009 at 5:07 am and is filed under Therapy. You can follow any responses to this entry through the RSS 2.0 feed.